ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1148

Prevalence and Risk Factors of Insufficiency Fractures of the Foot and Ankle Joint in Rheumatic and Musculoskeletal Diseases

Bjoern Buehring1, Nadine Al-Azem1, Ioana Andreica1, David Kiefer2, Uta Kiltz1, Styliani Tsiami1, Xenofon Baraliakos1 and Juergen Braun1, 1Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, 2Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Essen, Germany

Meeting: ACR Convergence 2021

Keywords: Bone density, Fracture, Insufficiency Fracture, Magnetic resonance imaging (MRI), osteoporosis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 8, 2021

Session Title: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster (1135–1149)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: Unlike fragility fractures, high-trauma and insufficiency fractures (IF) are not classically considered osteoporotic fractures. Patients with rheumatic and musculoskeletal diseases (RMD), especially those with rheumatoid arthritis (RA), are at increased risk of IF due to factors associated with reduced bone quality including chronic inflammation, medication, and altered biomechanics. IF frequently occur in ankle joints and feet. These fractures are often not detected in conventional radiographs, magnetic resonance imaging (MRI) is thought to be more sensitive.

The aim of this study was (i) to determine the frequency of IF in symptomatic ankles and feet of patients presenting to a tertiary hospital, to (ii) identify possible risk factors and (iii) to compare the IF detection rate of radiographs and MRI.

Methods: Using a retrospective study design, data of patients who had undergone MRI scans of the ankle/foot region between 2016 and 2018 were analyzed. Patients with IF were matched with 2 control subjects based on sex, age, and diagnosis and pertinent data was extracted from their medical records. Statistical analyses included T tests, chi-square tests, and regression analyses.

Results: In a total of 1471 foot and 281 ankle joint MRIs, 129 (7.4%) IF were detected. The mean age of patients with IF was 59 years, 82.9% were women. Among patients with IF 80,6% had a chronic inflammatory rheumatic disease (CIRD) which was significantly more frequent than non-CIRD diseases (19,4%, p< 0,001). Potential risk factors for IF were: low bone density indicative of osteoporosis (IF 42.6% vs. controls 16.2%, p< 0.001), history of previous fracture (34.9% vs. 8.6%, p< 0.001), smoking (37.3% vs. 23.1%, p=0.005) and current methotrexate (MTX) therapy (42.6% vs. 27.9%, p=0.005). Of the 96 (74.4%) IF patients who also had x-rays of the ankle/foot region, 24 (25%) had an IF diagnosis in the x-ray report.

Conclusion: With a frequency of 7.4%, IF are a relatively common cause of foot/ankle pain in patients with RMD who underwent MRI after presenting to a tertiary rheumatology hospital. Risk factors for IF largely corresponded to established risk factors for osteoporosis. The potential negative influence of MTX needs further research. Future studies should investigate whether the occurrence of IF represents an indication for anti-osteoporotic therapy and whether such treatment improves fracture healing and lowers the risk of future fractures.

Patient demographics BMI – body mass index, RA – rheumatoid arthritis, PsoA – psoriatic arthritis, CIRD – chronic inflammatory rheumatic disease, MTX – methotraxate


Disclosures: B. Buehring, None; N. Al-Azem, None; I. Andreica, None; D. Kiefer, None; U. Kiltz, AbbVie, 2, 5, 6, Biocad, 2, 6, Eli Lilly, 2, 6, Grünenthal, 2, 6, Janssen, 2, 6, MSD, 2, 6, Amgen, 5, Biogen, 5, Fresenius, 5, GlaxoSmithKline, 5, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, Roche, 2, 6, UCB, 2, 6, Hexal, 2, 5, Chugai, 2, 5; S. Tsiami, None; X. Baraliakos, AbbVie, 2, 5, 6, Chugai, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, UCB, 2, 5, 6, Bristol-Myers Squibb, 2, 5, 6, Celegene, 2, 5, 6, Merck, 2, 6, Werfen, 2; J. Braun, Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, Medac, MSD (Schering-Plough),, 2, 5, 6, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis and UCB, 2, 5, 6, Mundipharma, 2, 5.

To cite this abstract in AMA style:

Buehring B, Al-Azem N, Andreica I, Kiefer D, Kiltz U, Tsiami S, Baraliakos X, Braun J. Prevalence and Risk Factors of Insufficiency Fractures of the Foot and Ankle Joint in Rheumatic and Musculoskeletal Diseases [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/prevalence-and-risk-factors-of-insufficiency-fractures-of-the-foot-and-ankle-joint-in-rheumatic-and-musculoskeletal-diseases/. Accessed February 6, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-and-risk-factors-of-insufficiency-fractures-of-the-foot-and-ankle-joint-in-rheumatic-and-musculoskeletal-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences